HeartBeam Inc. (NASDAQ: BEAT) has recently been granted two new U.S. patents, enhancing its intellectual property portfolio and supporting its mission to revolutionize remote cardiac diagnostics. These patents cover the company's compact, cable-free 3D ECG device and a sophisticated rhythm analysis algorithm designed to detect arrhythmias through continuous signal input. This development underscores HeartBeam's commitment to advancing digital cardiac care and improving patient outcomes outside traditional medical facilities.
The 3D ECG device, notable for its use of chest and finger electrodes to capture high-fidelity signals in three dimensions, is tailored for on-demand symptom recording and 12-lead ECG synthesis. Currently under FDA review, the device's software has been validated by the VALID-ECG pivotal study, promising a new era of precision in cardiac diagnostics. The rhythm algorithm complements this by enabling targeted data collection during abnormal rhythm detection, thereby enhancing diagnostic accuracy across various cardiac monitoring systems.
With a total of 20 issued patents and 34 additional filings, HeartBeam is positioning itself as a leader in the digital cardiac care space. The company's future plans include integrating AI capabilities to further refine diagnostic accuracy, signaling a transformative shift in how cardiac health is monitored and managed. These advancements not only represent a leap forward in medical technology but also offer the potential to significantly reduce the burden on healthcare systems by enabling early detection and intervention for cardiac conditions.
